B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44

Benzinga Newsdesk www.benzinga.com Positive 77.5%

Neg 0% Neu 0% Pos 77.5%

B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $40 to $44.